Cooperative Newborn Screening System Priorities Program (NBS Co-Propel)
ID: 349438Type: Posted
Overview

Buyer

Health Resources and Services Administration (HHS-HRSA)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349438
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Nov 21, 2023 12:00 AM
  4. 4
    Due Feb 23, 2024 12:00 AM
Description

The Health Resources and Services Administration is offering funding through the Cooperative Newborn Screening System Priorities Program (NBS Co-Propel). This program aims to strengthen the newborn screening (NBS) system to provide screening, counseling, and health care services to newborns and children with, or at risk for, heritable disorders. The funding will support up to 10 recipients to address state/territory-specific challenges and pursue priorities to enhance, improve, and expand their NBS System. It will also focus on increasing timely collection and reporting of NBS specimens to improve early diagnosis and treatment for individuals with heritable conditions identified through NBS. Additionally, the funding will support long-term follow-up for individuals with Severe Combined Immunodeficiency (SCID) and other NBS conditions, linking public health agencies, clinicians, and engaging families. The program objectives include increasing the number of NBS specimens collected within 48 hours of birth, improving the communication of presumptive positive results for time-critical conditions, and increasing the reporting of NBS results within 7 days of birth. The program also aims to develop data collection plans to measure the percentage of 3-year-old children with at least one heritable condition identified through NBS who are thriving. Organizations in the United States, including state or political subdivisions, territories, health facilities or programs operated by or pursuant to a contract with or grant from the Indian Health Services, and other entities with appropriate expertise in NBS, are eligible to apply. The deadline for applications is February 23, 2024. For more information, please visit the following link: link. For any inquiries, contact Loraine Swanson, MPH at (404)234-3557 or email LSwanson@hrsa.gov.

Point(s) of Contact
LSwanson@hrsa.gov
Files
Title
Posted
MCHB HRSA-24-052 (UC1) NBS Co-Propel_Appendix A_updated 1 30 24.pdf
4/10/2024
Similar Opportunities
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)". This grant aims to support research that focuses on the development of new screening approaches and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. The grant also seeks to address "high priority" genetic conditions where screening may be possible in the near future. The grant emphasizes the importance of accurate screening tests and demonstrating the benefits of early intervention or treatment for including a condition on a newborn screening panel. The funding instrument for this opportunity is a grant, and there is no cost sharing or matching requirement. The category of funding activity is Income Security and Social Services. The opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The closing date for this grant opportunity is November 5, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-21-353.html](http://grants.nih.gov/grants/guide/pa-files/PAR-21-353.html). For any inquiries, please refer to the contact information provided in Section VII. Agency Contacts within the full opportunity announcement.
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)". This grant aims to support research focused on the development of new screening approaches and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. The grant also targets "high priority" genetic conditions where screening may be possible in the near future. The grant encourages the development of accurate screening tests and the demonstration of the benefits of early intervention or treatment for these conditions. The maximum award ceiling for this grant is $275,000. Eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for applications is November 16, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-21-355.html](http://grants.nih.gov/grants/guide/pa-files/PAR-21-355.html). For any inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health is offering a grant for the study of the natural history of disorders that can be screened in newborns. This funding opportunity aims to develop studies that will provide a comprehensive understanding of the sequence and timing of symptoms and complications of these disorders. By defining the natural history of these disorders, interventions for infants identified through newborn screening can be improved. The grant also encourages research on genotype-phenotype correlations and identification of modifying genetic, epigenetic, or environmental factors that contribute to clinical outcomes. The ultimate goal is to enhance diagnosis, treatment, and support for affected individuals and their families. For more information, visit the [grant announcement](http://grants.nih.gov/grants/guide/pa-files/PAR-21-115.html).
Enhancing Timely Data Reporting, Quality, and Use in Early Hearing Detection and Intervention (EHDI) Surveillance
Active
Centers for Disease Control - NCBDDD
The Centers for Disease Control - NCBDDD is offering a forecasted federal grant opportunity titled "Enhancing Timely Data Reporting, Quality, and Use in Early Hearing Detection and Intervention (EHDI) Surveillance". This grant aims to support jurisdictional Early Hearing Detection and Intervention (EHDI) programs in improving data quality and use to inform programmatic actions. The grant seeks to enhance the timeliness and completeness of data to ensure that infants who are born Deaf or Hard of Hearing (D/HH) receive timely screening, diagnosis, and access to early intervention within the first 6 months of life. Additionally, a subset of jurisdictions will integrate language and communication status data at age 3 years within their EHDI surveillance system to monitor the impact of early diagnosis and intervention for D/HH individuals. The grant will focus on boosting state and local systems, improving data quality and systems, addressing gaps and disparities in screening and enrollment, and incorporating developmental status indicator outcomes into EHDI surveillance. The estimated total program funding is $35,200,000, with an expected number of 39 awards. The grant application deadline is March 14, 2025, and the estimated award date is June 2, 2025. For more information, contact Deidra Green at deg4@cdc.gov.
Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)". This grant falls under the category of Income Security and Social Services. The purpose of this initiative is to promote the screening, functional validation, and characterization of birth defects-associated genetic variants identified through public-facing databases and individual efforts. The grant aims to utilize in-silico tools, appropriate animal models, in vitro systems, or multi-pronged approaches to study these genetic variants. The funding instrument for this grant is a Grant, and there is no cost sharing or matching requirement. The eligible applicants for this grant include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant opportunity is May 7, 2025. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-21-229.html](http://grants.nih.gov/grants/guide/pa-files/PAR-21-229.html).